Avalo Announces Participation in September Investor Conferences
September 04, 2024 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024 07:00 ET
|
Avalo Therapeutics
Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief...
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical...
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024 07:00 ET
|
Avalo Therapeutics
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with...
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. “We are...
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 07:30 ET
|
Avalo Therapeutics
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 ...
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024 07:00 ET
|
Avalo Therapeutics
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of...
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024 16:01 ET
|
Avalo Therapeutics
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024 16:01 ET
|
Avalo Therapeutics
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private...